


## Uracil-<sup>13</sup>C<sub>4</sub>,<sup>15</sup>N<sub>2</sub>

<b>Cat. No.:</b>	HY-I0960S3
<b>CAS No.:</b>	202407-06-5
<b>Molecular Formula:</b>	<sup>13</sup> C <sub>4</sub> H <sub>4</sub> <sup>15</sup> N <sub>2</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	118.04
<b>Target:</b>	Endogenous Metabolite
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Uracil- <sup>13</sup> C <sub>4</sub> , <sup>15</sup> N <sub>2</sub> is the <sup>13</sup> C and <sup>15</sup> N labeled Uracil[1]. Uracil is a common and naturally occurring pyrimidine derivative and one of the four nucleobases in the nucleic acid of RNA[2].
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-216.
- [2]. Pałasz A, et al. In search of uracil derivatives as bioactive agents. Uracils and fused uracils: Synthesis, biological activity and applications. *Eur J Med Chem*. 2015 Jun 5;97:582-611.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA